Skip to main content
Full access
Communications and Updates
Published Online: 1 May 2011

Development of Obsessive-Compulsive Disorder Following a Pineal Germinoma: A Case Report

To the Editor: Research on obsessive-compulsive neurobiology has focused on the orbitofrontal cortex and the basal ganglia, and less attention has been given to the functioning of the pineal body. A recent article by Vijay A. Mittal, Ph.D., and colleagues in the September 2010 issue of the Journal described a pediatric case in which a pineal region tumor was associated with simultaneous onset of obsessive-compulsive and psychotic symptoms (1). We report on the case of an adolescent with obsessive-compulsive and anxiety symptoms that emerged immediately subsequent to oncological treatment for a pineal germinoma.
“Jonathan” is a 16-year-old young man who presented with severe obsessive-compulsive symptoms, including contamination fears, cleaning rituals, scrupulosity, and checking compulsions, as well as significant generalized anxiety and depressive symptoms. Approximately 3.5 years before presenting to our clinic, Jonathan was diagnosed with a pineal germinoma. Before this diagnosis, he reported no obsessive-compulsive or anxiety symptoms of note and no relevant developmental issues. Jonathan completed radiation therapy and chemotherapy per protocol ACNS0232. Treatment of the germinoma was successful; a multiplanar multisequential brain MRI with and without contrast 2 years after treatment showed a stable postoperative appearance without evidence of tumor recurrence, and no other substantial changes in brain structure were observed. Immediately after completing the germinoma treatment protocol, Jonathan exhibited a dramatic onset of obsessive-compulsive symptoms in the absence of any immune triggers. At the time he presented to our clinic, he was taking fluoxetine (40 mg/day), duloxetine (90 mg/day), and risperidone (1 mg/day), which were collectively associated with partial response.
The timing of symptom onset suggests a possible association of obsessive-compulsive symptoms with pineal body functioning and its associated neurotransmitter, melatonin. In their case report, Mittal et al. (1) considered the obsessive-compulsive symptoms that developed after a pineal tumor to be possibly related to a basal ganglia stroke that occurred concurrently with the tumor. That did not occur in our case. While pineal functioning has received relatively little attention in obsessive-compulsive disorder (OCD), several lines of converging evidence may suggest relevance. First, case reports have focused on pineal lesion effects in anorexia nervosa (2), which has high comorbidity and some etiological concordance with OCD. Second, melatonin may alter serotonin metabolism (3), and melatonin disturbance has been reported in OCD (4). This case contributes to a small but growing evidence base for pineal gland functioning in the pathogenesis of OCD and related disorders and indicates future work to assess the relationship between melatonin and other biological mediators in OCD (e.g., serotonin).

Footnote

Accepted for publication in March 2011.

References

1.
Mittal VA, Karlsgodt K, Zinberg J, Cannon TD, Bearden CE: Identification and treatment of a pineal region tumor in an adolescent with prodromal psychotic symptoms. Am J Psychiatry 2010; 167:1033–1037
2.
Uher R, Treasure J: Brain lesions and eating disorders. J Neurol Neurosurg Psychiatry 2005; 76:852–857
3.
Miguez JM, Martin FJ, Aldegunde M: Melatonin effects on serotonin synthesis and metabolism in the striatum, nucleus accumbens, and dorsal and median raphe nuclei of rats. Neurochem Res 1987; 22:87–92
4.
Monteleone P, Catapano F, Del Buono G, Maj M: Circadian rhythms of melatonin, cortisol, and prolactin in patients with obsessive-compulsive disorder. Acta Psychiatr Scand 1994; 89:411–415

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 550
PubMed: 21536703

History

Accepted: March 2011
Published online: 1 May 2011
Published in print: May 2011

Authors

Details

Alessandro S. De Nadai, M.A.
Eric A. Storch, Ph.D.
Jeffrey L. Alvaro, M.D.

Funding Information

Mr. De Nadai reports no financial relationships with commercial interests. Dr. Storch has received grant funding from the All Children's Hospital Research Foundation, Centers for Disease Control and Prevention, International OCD Foundation, Janssen Pharmaceuticals, National Alliance for Research on Schizophrenia and Affective Disorders, NIMH, National Institute of Child Health and Human Development, and the Tourette Syndrome Association; receives textbook honoraria from Lawrence Erlbaum and Springer publishers; and has been an educational consultant for Rogers Memorial Hospital and receives research support from the All Children's Hospital Guild Endowed Chair and the University of South Florida. Dr. Alvaro is on the speakers bureaus for Novartis Pharmaceuticals and Shire Pharmaceuticals.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share